FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average h	nurden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GOLDSTEIN JOSEPH L						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [ REGN ]											of Reportin icable) or r (give title	ng Person(s) to Is			
(Last) 777 OLI	`	irst) LL RIVER ROA	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/26/2012  below) below)													specify		
(Street)	ΓOWN N	Y	10591		-   4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)											vidual or Joint/Group Filing (Check Applicat Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)																		
1. Title of S	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  Security (Instr. 3)  2. Transaction Date (Month/Day/Year) (M							n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership												
										Code	v	Amount		A) or D)	Price	Transa	orted (Instr. 4) isaction(s) tr. 3 and 4)				
Common	Stock			03/26	6/2012	2				M <sup>(1)</sup>		5,000	) A \$1		\$18.6	51 5	,000	00 D			
Common	Stock			03/26	6/2012	2				S <sup>(1)</sup>		5,000		D	\$120	)	0	D D			
		T										sed of onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				Ex	Date Exe (piration I lonth/Day	Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e Or s Fo lly Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da Ex	ate kercisable		xpiration ate	Title		Amount or Number of Shares						
Non- Qualified Stock Option (right to	\$18.61	03/26/2012			M <sup>(1)</sup>			5,000		(2)	0:	1/02/2019	Comn		5,000	(3)	0		D		

## Explanation of Responses:

- $1.\ Disposition/acquisition\ made\ pursuant\ to\ a\ plan\ intended\ to\ comply\ with\ Rule\ 10b5-1(c).$
- 2. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant
- 3. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

/s/\*\*Joseph L. Goldstein 03/26/2012

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.